Tagged with IOT

Global One of the doyens of European biotech is stepping back from general management. Jean-Paul Clozel founded rare disease focused Actelion along with his wife Martine Clozel in 1997, a company that went on to become publicly traded and launch three blockbuster drugs. The Clozels then sold up to J&J for…

China After a glittering career in corporate America, in 2011 Jasmine Cui returned to China and in 2015 launched her own biotech, Innocare. The firm, which focuses on oncology and autoimmune disease R&D, now has an extensive pipeline, with a BTK inhibitor for hematological cancers holding particular potential. In conversation with…

China Boan Biotech CEO Jiang Hua outlines the Luye Pharma-acquired company’s approach, securing stable revenues through its biosimilars while pursuing novel platforms and innovative drug development. She provides insights into the biotech’s six biosimilar products, as well as its main technology platforms – including the foundational Human Antibody Transgenic Mouse platform…

Global Marijn Verhoef, Director of Operations and Research at the Access to Medicine Foundation examines the interconnected challenges of drug shortages and antimicrobial resistance. Verhoef urges decisive and urgent action from the pharma companies that manufacture lifesaving antibiotics and antifungals to ensure that patients can get the right medicine when they…

China BeiGene may not be a profitable business quite yet, but the Chinese biotech has two top oncology products and saw its sales soar to USD 2.2 billion in 2023. Having set its sights on markets outside of China, with its BTK inhibitor Brukinsa already approved across multiple geographies, the company…

China Cytiva is a global leader in bioprocessing technologies and services that support the manufacturing and research of biopharmaceuticals. China is a key market in the company’s growth story, where – as President of Cytiva in China Allen Li notes – it has shifted from simply offering superior products to engaging…

China Unlike many of its Chinese biotech peers with broad portfolios, Hua Medicine has focused intensively on developing a single product, dorzagliatin, for diabetes. As CEO Li Chen notes, this strategic concentration has allowed Hua Medicine to pioneer in homeostasis control modulation and address specific unmet medical needs in diabetes treatment,…

China HKEX-main board listed Alphamab Oncology is one of China’s leading biotech success stories, having developed and marketed the world’s first subcutaneously injectable PD-L1 inhibitor. Founder, Chairman, and CEO Dr Xu Ting outlines some of the key recent trends in the Chinese biotech ecosystem, the funding challenges associated with running clinical trials…

China Chinese player Legend Biotech reached a new turning point last month when its Johnson & Johnson-partnered Carvykti became the first BCMA-targeted CAR-T cell therapy to be approved by the FDA for second-line treatment of multiple myeloma. From its original roots in China to its first FDA approval in 2022, the…

Global Having been quietly working away on its mRNA platform for years, Moderna stepped into the limelight during the COVID-19 pandemic and became a commercial-stage outfit almost overnight with its vaccine. After generating sales of USD 18.4 billion in 2022, demand for the company’s Spikevax shot, still its only commercialized product…

Switzerland While the Swiss biotech sector is inevitably facing many of the same funding challenges as the global industry and is still struggling to make a meaningful comeback from its 2022 slump, the latest report from the Swiss Biotech Association and EY shows the sector’s resilience with the record revenues of…

Hong Kong VMS Group was founded in 2006 and since then has built close relationships with a handful of large anchor investors, including some of the largest families in Hong Kong. Apart from managing over USD 4.3 billion across its three in-house strategies – Private Equity, Real Estate and Structured Finance, it…